MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-21-2026
Innate Pharma S.A. Operating Cash Flow 2011-2026 | IPHA
Annual Operating Cash Flow Innate Pharma S.A.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | -58.5 M | -51.8 M | 34.9 M | -32.5 M | -48.1 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 34.9 M | -58.5 M | -31.2 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 0.82 | -3.48 % | $ 4.47 M |  China |
 |
Rigel Pharmaceuticals
RIGL
|
75.7 M | $ 33.23 | -4.03 % | $ 584 M |  USA |
 |
Graybug Vision
GRAY
|
-21.2 M | - | -11.23 % | $ 9.65 M | USA |
 |
I-Mab
IMAB
|
-1.3 B | - | - | $ 866 M | China |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Apellis Pharmaceuticals
APLS
|
45.3 M | $ 20.15 | -2.68 % | $ 2.54 B | USA |
 |
AbCellera Biologics
ABCL
|
-131 M | $ 3.72 | -2.75 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-57.3 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-93.4 M | $ 163.7 | -1.61 % | $ 8.14 B | USA |
 |
BridgeBio Pharma
BBIO
|
-446 M | $ 64.66 | -1.37 % | $ 12.4 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-9.09 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 8.52 | -2.46 % | $ 1.39 B | Britain |
 |
Adverum Biotechnologies
ADVM
|
-92.5 M | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-72.5 M | - | - | $ 3.45 B | USA |
 |
Avid Bioservices
CDMO
|
11 M | - | - | $ 789 M | USA |
 |
Certara
CERT
|
96.3 M | $ 7.16 | 1.49 % | $ 1.15 B | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
-31.1 M | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-19.4 M | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
-196 M | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-53.7 M | - | - | $ 231 M | USA |
 |
Capricor Therapeutics
CAPR
|
-25.6 M | $ 25.91 | -3.56 % | $ 694 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
209 M | $ 24.0 | 0.5 % | $ 2.93 B | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-49.4 M | $ 0.99 | -3.28 % | $ 72.7 M | USA |
 |
Corvus Pharmaceuticals
CRVS
|
-23.9 M | $ 17.75 | -0.79 % | $ 852 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
-81.2 M | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-10.4 M | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-7.99 M | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-7.99 M | - | -4.36 % | $ 27 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-147 M | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-733 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-8.58 M | - | 5.93 % | $ 314 M | Canada |
 |
Denali Therapeutics
DNLI
|
-348 M | $ 20.02 | -4.67 % | $ 3.29 B | USA |
 |
AgeX Therapeutics
AGE
|
-7.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-169 M | - | - | $ 1.01 B | USA |
 |
Eton Pharmaceuticals
ETON
|
6.82 M | $ 17.54 | -3.36 % | $ 450 M | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-43 M | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
-8.97 M | - | 7.55 % | $ 38.1 M | USA |